Antibody-drug conjugates in gynecologic malignancies

Elizabeth K Lee; Joyce F Liu

doi:10.1016/j.ygyno.2019.03.245

Antibody-drug conjugates in gynecologic malignancies

Gynecol Oncol. 2019 Jun;153(3):694-702. doi: 10.1016/j.ygyno.2019.03.245. Epub 2019 Mar 28.

Authors

Elizabeth K Lee¹, Joyce F Liu²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: joyce_liu@dfci.harvard.edu.

PMID: 30929824
DOI: 10.1016/j.ygyno.2019.03.245

Abstract

Antibody drug conjugates (ADCs) are an exciting class of oncologic therapeutics. ADCs have been FDA approved in hematologic malignancies and breast cancer and are a growing area of study in numerous solid malignancies. The desire for tumor-specific therapies with decreased systemic toxicity has driven over a decade of research into the design and optimization of ADCs, which are now in a third generation of development. Gynecologic malignancies in particular suffer a dearth of novel therapies. This review will examine the field of ADCs in gynecologic cancers, focusing on ADCs targeting folate receptor alpha (FRα), mesothelin, tissue factor, MUC16 (CA125), NaPi2B, and Trop2.

Keywords: Antibody-drug conjugates; Cervical cancer; Endometrial cancer; Ovarian cancer.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, Neoplasm
CA-125 Antigen
Camptothecin / analogs & derivatives
Camptothecin / therapeutic use
Cell Adhesion Molecules / antagonists & inhibitors
Drug Design
Female
Folate Receptor 1 / antagonists & inhibitors
GPI-Linked Proteins / antagonists & inhibitors
Genital Neoplasms, Female / drug therapy*
Humans
Immunoconjugates / therapeutic use*
Maytansine / analogs & derivatives*
Maytansine / therapeutic use
Membrane Proteins / antagonists & inhibitors
Mesothelin
Sodium-Phosphate Cotransporter Proteins, Type IIb / antagonists & inhibitors
Thromboplastin / antagonists & inhibitors

Substances

Antibodies, Monoclonal, Humanized
Antigens, Neoplasm
CA-125 Antigen
Cell Adhesion Molecules
DMUC5754A
Folate Receptor 1
GPI-Linked Proteins
Immunoconjugates
MUC16 protein, human
Membrane Proteins
SLC34A2 protein, human
Sodium-Phosphate Cotransporter Proteins, Type IIb
TACSTD2 protein, human
Maytansine
Thromboplastin
mirvetuximab soravtansine
Mesothelin
anetumab ravtansine
sacituzumab govitecan
Camptothecin